Literature DB >> 16215439

Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases.

Federica Villa1, Maria Grazia Rumi, Clementina Signorelli, Simone Saibeni, Ersilio Del Ninno, Stefano Ferrero Bogetto, Roberto de Franchis, Maurizio Vecchi.   

Abstract

We report two patients who developed an inflammatory bowel disease (IBD) shortly after beginning combined alpha-interferon and ribavirin treatment for HCV-related chronic hepatitis. The previous clinical history was negative for IBD in both patients, who developed diarrhoea and rectal bleeding 10 days and 6 months, respectively, after the initiation of therapy. The history, therapeutic management and the possible causal relationships of these cases are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16215439     DOI: 10.1097/00042737-200511000-00015

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Concomitant therapy of Crohn's disease and hepatitis C with budesonide and antivirals.

Authors:  Alok Gupta; Michael D Sitrin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-08

Review 2.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

3.  Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis.

Authors:  Jay Luther; Stephanie Y Owyang; Tomomi Takeuchi; Tyler S Cole; Min Zhang; Maochang Liu; John Erb-Downward; Joel H Rubenstein; Chun-Chia Chen; Anna V Pierzchala; Jose A Paul; John Y Kao
Journal:  Gut       Date:  2011-04-06       Impact factor: 23.059

4.  Acute Severe Ulcerative Colitis After mRNA Coronavirus Disease 2019 Vaccination: Can mRNA Vaccines Unmask Inflammatory Bowel Diseases?

Authors:  Çağatay Ak; Süleyman Sayar; Gupse Adalı; Kamil Özdil
Journal:  ACG Case Rep J       Date:  2022-07-01

5.  Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.

Authors:  Alina M Allen; W Ray Kim; Joseph Larson; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

Review 6.  Hepatitis C virus and inflammatory bowel disease.

Authors:  Todd L Horn; Joel Reynolds; Willem de Villiers; Luis R Peña
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

Review 7.  Secondary causes of inflammatory bowel diseases.

Authors:  Yezaz A Ghouri; Veysel Tahan; Bo Shen
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

8.  Large intestine histopathology of pegylated-interferon-alpha plus ribavirin treated chronic hepatitis C patients.

Authors:  Konstantinos D Pantazis; Ioannis S Elefsiniotis; Dimitrios Papaioannou; Hero Brokalaki; Gerasimos Bonatsos; Christos Mavrogiannis
Journal:  Gastroenterol Res Pract       Date:  2008       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.